Associated Papers
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
Soon Jian Hao J et al.
Cold Spring Harbor Molecular Case Studies, 2022
36577523 (PubMed )
Supplement: supp_mcs.a006223_Supplemental_Material.pdf
Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung.
Wang H et al.
Frontiers in Oncology, 2022
Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort.
Zhan Q et al.
Ebiomedicine, 2021
34839264 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Takeda M et al.
Oncotarget, 2018
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J et al.
Lung Cancer (amsterdam, Netherlands), 2016
Select a paper to view details